Table 3.
Patients receiving NRTI pairs in their initial antiretroviral therapy regimen (N = 2267).
| Class | Medication | Number (%) |
|---|---|---|
| NRTI pairs (N = 2267) | Abacavir/lamivudine | 55 (2) |
| Abacavir/zidovudine | 110 (5) | |
| Didanosine/lamivudine | 35 (2) | |
| Didanosine/stavudine | 113 (5) | |
| Stavudine/lamivudine | 372 (16) | |
| Tenofovir/lamivudine | 579 (26) | |
| Zidovudine/lamivudine | 897 (40) | |
| Othera | 106 (5) |
Each patient is included once in the table. Emtricitabine and lamivudine are combined. NRTIs, nucleoside (tide) reverse transcriptase inhibitors.
a
Other includes all NRTI pairs received by less than 35 individuals.